Full Text View
Tabular View
No Study Results Posted
Related Studies
Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
This study has been completed.
Study NCT00029224   Information provided by Novartis
First Received: January 9, 2002   Last Updated: October 1, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Breast Cancer
Multiple Myeloma
Prostate Cancer
Additional conditions recognized in this trial
Breast Neoplasms
Neoplasms, Plasma Cell
Prostatic Neoplasms
More general conditions related to this trial
Blood Protein Disorders
Breast Diseases
Cardiovascular Diseases
Genital Diseases, Male
Genital Neoplasms, Male
Hematologic Diseases
Hemorrhagic Disorders
Hemostatic Disorders
Immune System Diseases
Immunoproliferative Disorders
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Paraproteinemias
Prostatic Diseases
Skin Diseases
Urogenital Neoplasms
Vascular Diseases
Interventions listed in this trial
zoledronic acid
Additional drug interventions recognized in this trial
Diphosphonates
More general drug interventions related to this trial
Bone Density Conservation Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sponsors listed in this trial
Novartis


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services